FDA-IMS Joint Workshop 
About the Workshop
The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and multiple myeloma remains a difficult disease to treat, so the need for new therapies remains. Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to facilitate future drug development and improve patient outcomes.

On November 8-9, 2022, the IMS will host a joint symposium with the FDA to provide a forum for open discussion among academia, industry, and regulatory agencies about clinical drug development in multiple myeloma. This workshop will discuss trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population.

In person registration is now full. You may still register online for live virtual access.

Virtual Platform Access
SCHEDULED MAINTENANCE: The virtual platform will be unavailable December 23-27, 2022 for scheduled maintenance. Access for all attendees will be extended until January 13, 2023. 

The virtual platform is now available at this link.

Existing Registrants: Log in to the platform with your email address; your password is your registration ID. If you are unable to locate your registration ID, please click the Contact Us button to the right.

New Registrants: Click on the above virtual platform link. Enter your email address. You will then be prompted to create an account. After finishing your profile, you will immediately be granted full access to the virtual platform.
Click below to access the meeting content.
IN PERSON Location
The Bethesdan Hotel
8120 Wisconsin Avenue
Bethesda, MD 20814
November 8-9, 2022

Processing Registration...